IL204922A0 - Methods for detecting major adverse cardiovascular and cerebrovascular events - Google Patents
Methods for detecting major adverse cardiovascular and cerebrovascular eventsInfo
- Publication number
- IL204922A0 IL204922A0 IL204922A IL20492210A IL204922A0 IL 204922 A0 IL204922 A0 IL 204922A0 IL 204922 A IL204922 A IL 204922A IL 20492210 A IL20492210 A IL 20492210A IL 204922 A0 IL204922 A0 IL 204922A0
- Authority
- IL
- Israel
- Prior art keywords
- adverse cardiovascular
- major adverse
- methods
- human
- cerebrovascular events
- Prior art date
Links
- 230000002411 adverse Effects 0.000 title abstract 4
- 230000007211 cardiovascular event Effects 0.000 title abstract 4
- 230000007213 cerebrovascular event Effects 0.000 title abstract 4
- 102000005720 Glutathione transferase Human genes 0.000 abstract 1
- 108010070675 Glutathione transferase Proteins 0.000 abstract 1
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 abstract 1
- 102100023123 Mucin-16 Human genes 0.000 abstract 1
- 102000002262 Thromboplastin Human genes 0.000 abstract 1
- 108010000499 Thromboplastin Proteins 0.000 abstract 1
- 102000013529 alpha-Fetoproteins Human genes 0.000 abstract 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
- H01J49/00—Particle spectrometers or separator tubes
- H01J49/0009—Calibration of the apparatus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/745—Assays involving non-enzymic blood coagulation factors
- G01N2333/7454—Tissue factor (tissue thromboplastin, Factor III)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
- Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
- Electrotherapy Devices (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99856307P | 2007-10-10 | 2007-10-10 | |
| US99875607P | 2007-10-11 | 2007-10-11 | |
| PCT/US2008/079553 WO2009049189A2 (en) | 2007-10-10 | 2008-10-10 | Methods for detecting major adverse cardiovascular and cerebrovascular events |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL204922A0 true IL204922A0 (en) | 2010-11-30 |
Family
ID=40289424
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL204922A IL204922A0 (en) | 2007-10-10 | 2010-04-08 | Methods for detecting major adverse cardiovascular and cerebrovascular events |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20110045514A1 (enExample) |
| EP (1) | EP2210108B1 (enExample) |
| JP (1) | JP2011501133A (enExample) |
| CN (1) | CN101939651A (enExample) |
| AT (1) | ATE536553T1 (enExample) |
| AU (1) | AU2008310669A1 (enExample) |
| CA (1) | CA2702268A1 (enExample) |
| ES (1) | ES2374762T3 (enExample) |
| IL (1) | IL204922A0 (enExample) |
| WO (1) | WO2009049189A2 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8620738B2 (en) * | 2006-08-31 | 2013-12-31 | Visa U.S.A. Inc | Loyalty program incentive determination |
| GB0717637D0 (en) | 2007-09-10 | 2007-10-17 | Univ Leiden | Future cardiac event biomarkers |
| EP2199956A1 (en) * | 2008-12-18 | 2010-06-23 | Siemens Aktiengesellschaft | Method and system for managing results of an analysis process on objects handled along a technical process line |
| JP5728488B2 (ja) | 2009-11-13 | 2015-06-03 | ビージー メディシン， インコーポレイテッド | 心筋梗塞のリスクファクターおよび予測 |
| ES2728120T3 (es) * | 2010-01-29 | 2019-10-22 | Metanomics Gmbh | Medios y procedimientos para diagnosticar insuficiencia cardíaca en un sujeto |
| BR112012018771A2 (pt) * | 2010-01-29 | 2017-06-20 | Metanomics Gmbh | ''método para dianosticar insuficência cardíaca em um sujeito'' |
| CN106055895B (zh) * | 2010-09-15 | 2021-02-19 | Dh科技发展私人贸易有限公司 | 产物离子谱的数据独立获取及参考谱库匹配 |
| EP2592422A1 (en) * | 2011-11-08 | 2013-05-15 | Zora Biosciences OY | Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment |
| EP3968026A1 (en) | 2012-03-26 | 2022-03-16 | XCellCure, LLC | Device and method for detection of analytes |
| AU2014227891A1 (en) * | 2013-03-15 | 2015-10-08 | Sera Prognostics, Inc. | Biomarkers and methods for predicting preterm birth |
| KR101660328B1 (ko) | 2014-01-14 | 2016-09-27 | 한국과학기술연구원 | 심혈관 질환 진단용 바이오 마커 |
| US9933425B2 (en) | 2014-04-10 | 2018-04-03 | MEP Equine Solutions LLC | Method for the quantification of parasite eggs in feces |
| EP3172564A4 (en) * | 2014-07-18 | 2018-06-27 | Genova Diagnostics, Inc. | Use of an evidence-based, translational algorithm to, inter alia, assess biomarkers |
| US20180238914A1 (en) * | 2015-08-19 | 2018-08-23 | Metanomics Gmbh | Means and methods for diagnosing cardiac disease in a subject |
| WO2017028308A1 (en) * | 2015-08-20 | 2017-02-23 | Bgi Shenzhen | Biomarkers for coronary heart disease |
| CN105223264B (zh) * | 2015-09-21 | 2017-12-29 | 广东联捷生物科技有限公司 | 一种质谱定量分析的模拟内标方法、装置及应用 |
| CN105486778B (zh) * | 2016-01-25 | 2017-11-03 | 齐炼文 | 诊断区分稳定型心绞痛和急性冠脉综合征的代谢标志物 |
| CN105445408B (zh) * | 2016-01-25 | 2018-06-12 | 齐炼文 | 诊断区分冠状动脉粥样硬化和稳定型心绞痛的代谢标志物 |
| CN105866261A (zh) * | 2016-03-24 | 2016-08-17 | 中国药科大学 | 诊断区分稳定型心绞痛和急性冠脉综合征的代谢标志物群 |
| WO2017178453A1 (en) * | 2016-04-14 | 2017-10-19 | Roche Diagnostics Gmbh | Method for determining a concentration of a target analyte in a sample of bodily fluid |
| CA3087305A1 (en) * | 2017-12-13 | 2019-06-20 | Glx Analytix Aps | Biomarkers for multiple sclerosis |
| JP7280582B2 (ja) * | 2018-09-12 | 2023-05-24 | 株式会社島津製作所 | 心房細動指標値の測定方法 |
| CN109799296A (zh) * | 2019-01-28 | 2019-05-24 | 江南大学 | 一种用于细胞非靶向代谢组学分析的样品前处理方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| EP1904846A4 (en) | 2005-06-29 | 2009-03-18 | Rules Based Medicine Inc | METHOD AND KITS FOR THE DIAGNOSIS OF ACUTE CORONARY SYNDROME |
| WO2007124439A2 (en) * | 2006-04-21 | 2007-11-01 | Rules-Based Medicine, Inc. | Diagnosis of stroke using metalloproteinase or transaminase |
-
2008
- 2008-10-10 WO PCT/US2008/079553 patent/WO2009049189A2/en not_active Ceased
- 2008-10-10 AT AT08837800T patent/ATE536553T1/de active
- 2008-10-10 ES ES08837800T patent/ES2374762T3/es active Active
- 2008-10-10 JP JP2010529096A patent/JP2011501133A/ja not_active Withdrawn
- 2008-10-10 AU AU2008310669A patent/AU2008310669A1/en not_active Abandoned
- 2008-10-10 CN CN2008801210762A patent/CN101939651A/zh active Pending
- 2008-10-10 EP EP08837800A patent/EP2210108B1/en not_active Not-in-force
- 2008-10-10 US US12/682,492 patent/US20110045514A1/en not_active Abandoned
- 2008-10-10 CA CA2702268A patent/CA2702268A1/en not_active Abandoned
-
2010
- 2010-04-08 IL IL204922A patent/IL204922A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20110045514A1 (en) | 2011-02-24 |
| WO2009049189A3 (en) | 2009-06-18 |
| JP2011501133A (ja) | 2011-01-06 |
| EP2210108A2 (en) | 2010-07-28 |
| AU2008310669A1 (en) | 2009-04-16 |
| EP2210108B1 (en) | 2011-12-07 |
| CN101939651A (zh) | 2011-01-05 |
| WO2009049189A2 (en) | 2009-04-16 |
| ATE536553T1 (de) | 2011-12-15 |
| ES2374762T3 (es) | 2012-02-21 |
| CA2702268A1 (en) | 2009-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL204922A0 (en) | Methods for detecting major adverse cardiovascular and cerebrovascular events | |
| NZ593514A (en) | p-mTOR and p-AKT as Ratio Based Biomarkers for the Prognosis and/or Diagnosis of Cancer | |
| WO2009137015A3 (en) | Biomarkers of ionizing radiation | |
| TW200617380A (en) | Concentration determination in a diffusion barrier layer | |
| WO2013093635A3 (en) | Plasma micrornas for the detection of early colorectal cancer | |
| ATE548656T1 (de) | Verfahren zur identifizierung von patienten mit erhöhter wahrscheinlichkeit des auftretens eines ovarialkarzinoms und zusammensetzungen dafür | |
| JPWO2016163539A1 (ja) | 肝疾患の病態を判別する方法 | |
| BR112014016158A8 (pt) | medições exatas de analito para tira de teste eletroquímica com base na(s) característica(s) física(s) detectada(s) da amostra contendo o analito | |
| CA2701341A1 (en) | Method of assessing colorectal cancer from a stool sample by use of the marker combination calprotectin and hemoglobin/haptoglobin complex | |
| BR112016004320A2 (pt) | biossensor, sistema, kit, métodos de determinação ou de identificação e de quantificação de uma concentração de amônia ou íon amônio, de diagnóstico de uma doença metabólica em um sujeito, de determinação da resposta do paciente a uma terapia, de fabricação de um biossensor, de um sistema ou de qualquer tira de teste e de detecção da presença, ausência, ou quantidade de aminoácidos em uma amostra, e, tira de teste | |
| NZ578283A (en) | Proteomic profiling method useful for condition diagnosis and monitoring, composition screening, and therapeutic monitoring | |
| DE60129151D1 (de) | Verfahren zur erkennung von eierstockkrebs mittels menschlichem kallikrein (hk6) | |
| Paliwal et al. | A Study of Procalcitonin as an Early Predictor of Severity in Acute Pancreatitis. | |
| RU2019104870A (ru) | Комбинированный тест на наличие колоректального рака | |
| ATE492815T1 (de) | Diagnostik-biomolekül(e) | |
| MX2012007009A (es) | Método para diagnosticar un tumor maligno. | |
| ATE508364T1 (de) | Diagnoseverfahren für präeklampsie | |
| CA2623653A1 (en) | Use of n-myristoyltransferase on non-tumor tissue for cancer diagnosis | |
| US12007391B2 (en) | Means and methods for determining risk of type-1 diabetes by serum protein biomarkers | |
| Takeji et al. | Des‐gamma‐carboxy prothrombin identified by P‐11 and P‐16 antibodies reflects prognosis for patients with hepatocellular carcinoma | |
| WO2008035204A3 (en) | Prediction and prophylactic treatment of type 1 diabetes | |
| JP5133842B2 (ja) | 癌が疑われる患者または癌患者由来の組織の癌部と非癌部との判別方法およびそれに用いる判別試薬 | |
| US9903878B2 (en) | Biomarker for human prostate cancer | |
| WO2022271865A3 (en) | Protein biomarker indicators of neurological injury and/or disease and methods of use thereof | |
| Aydin et al. | Predictive value of immature granulocyte percentage and neutrophil lymphocyte ratio in terms of prognosis in the course of acute pancreatitis. |